| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥579.3B | ¥524.2B | +10.5% |
| Operating Income | ¥145.6B | ¥126.0B | +15.6% |
| Ordinary Income | ¥150.7B | ¥131.6B | +14.6% |
| Net Income | ¥106.9B | ¥91.7B | +16.6% |
| ROE | 9.4% | 8.8% | - |
FY2026 Q3 cumulative results: Revenue 57,929 million yen (YoY +10.5%), Operating Income 14,563 million yen (+15.6%), Ordinary Income 15,074 million yen (+14.6%), Net Income 10,689 million yen (+16.6%). The company delivered strong revenue and profit growth, with operating margin reaching 25.1%, substantially higher than the prior year's 24.0%. Revenue growth of 10.5% was driven by expansion in the Electronic Materials and Functional Chemicals segment, which increased 26.6% YoY to 31,532 million yen. The Life Science segment experienced a slight decline of 4.0% to 26,397 million yen. Operating income increased faster than revenue due to improved profitability, particularly from the Electronic Materials segment where operating profit surged 21.2% to 12,451 million yen. The company maintained strong cash generation with operating cash flow of 15,177 million yen, representing 1.42 times net income, and free cash flow of 8,646 million yen after capital expenditures of 2,941 million yen.
Revenue increased 5,508 million yen (+10.5% YoY) to 57,929 million yen, driven predominantly by the Electronic Materials and Functional Chemicals segment. This segment grew 6,617 million yen (+26.6%) from 24,916 million yen to 31,532 million yen, overtaking Life Science as the larger revenue contributor. The Life Science segment declined 1,108 million yen (-4.0%) from 27,505 million yen to 26,397 million yen. The strong performance in Electronic Materials reflects robust demand in semiconductor and electronics applications, while the Life Science segment faced headwinds possibly from market conditions or product mix changes. Operating income rose 1,968 million yen (+15.6%) to 14,563 million yen, with operating margin improving 1.1 percentage points from 24.0% to 25.1%. The Electronic Materials segment's operating profit increased 2,180 million yen (+21.2%) to 12,451 million yen, with segment margin improving from 41.2% to 39.5%. Life Science segment profit decreased 117 million yen (-2.9%) to 3,907 million yen, with margin declining from 14.6% to 14.8%. Corporate overhead costs increased 95 million yen to 1,795 million yen. Non-operating income contributed a net positive 511 million yen, primarily from interest income of 631 million yen and equity method gains, partially offset by foreign exchange losses. The difference between ordinary income (15,074 million yen) and operating income (14,563 million yen) of 511 million yen represents 3.4% of operating income, a modest but positive contribution. Extraordinary income of 185 million yen from investment securities sales provided additional uplift, bringing net income to 10,689 million yen after tax expenses of 4,489 million yen (effective tax rate 29.6%). This represents a revenue up/profit up pattern with operating leverage demonstrated through margin expansion.
The company operates two reporting segments: Life Science and Electronic Materials and Functional Chemicals. Electronic Materials and Functional Chemicals generated revenue of 31,532 million yen (54.4% of total) and operating profit of 12,451 million yen with a segment margin of 39.5%, making it the core business by both revenue share and profitability. This segment's operating profit accounts for 76.1% of total segment profit before corporate adjustments. Life Science contributed revenue of 26,397 million yen (45.6% of total) with operating profit of 3,907 million yen at a 14.8% margin. The Electronic Materials segment demonstrates significantly higher profitability with a 24.7 percentage point margin advantage over Life Science (39.5% vs 14.8%). Year-over-year, Electronic Materials showed stronger momentum with revenue growth of 26.6% and profit growth of 21.2%, while Life Science experienced revenue decline of 4.0% and profit decline of 2.9%. The divergent performance reflects different market dynamics, with electronic materials benefiting from semiconductor and electronics industry demand expansion, while life science products face more challenging conditions. Corporate overhead of 1,795 million yen (12.3% of segment profit) reduced consolidated operating income to 14,563 million yen.
[Profitability] ROE 9.4% improved from the prior year level and exceeds the manufacturing industry median of 5.0%. Net profit margin of 18.5% significantly outperforms the industry median of 6.3%, ranking in the top tier of profitability. Operating margin of 25.1% is substantially higher than the industry median of 8.3%, reflecting strong pricing power and operational efficiency, up 1.1 percentage points from 24.0% YoY. Gross profit margin stood at 38.5% with gross profit of 22,320 million yen. [Cash Quality] Cash and equivalents totaled 36,726 million yen, providing 1.82 times coverage of short-term debt and strong liquidity buffer. Operating cash flow of 15,177 million yen represents 142% of net income, indicating high-quality, cash-backed earnings. Cash conversion ratio of 0.69 (operating CF to EBITDA) falls below the industry median of 1.24, warranting attention to working capital efficiency. [Investment Efficiency] Asset turnover of 0.388 is below the industry median of 0.58, indicating room for improvement in asset utilization. Return on assets of 7.2% exceeds the industry median of 3.3%. Return on invested capital of 9.7% compares favorably to the industry median of 5.0%. Financial leverage of 1.32 times is lower than the industry median of 1.53 times, reflecting conservative capital structure. [Financial Health] Equity ratio of 75.7% substantially exceeds the industry median of 63.8%, indicating strong financial stability. Current ratio of 373.7% and quick ratio of 306.6% demonstrate robust short-term liquidity, well above the industry median current ratio of 2.84 times. Debt-to-equity ratio of 0.12 is very low, indicating minimal leverage. Interest coverage ratio exceeds 153 times, providing substantial cushion for debt service.
Operating cash flow of 15,177 million yen represents 1.42 times net income of 10,689 million yen, confirming strong cash-backed earnings quality. The company generated robust cash from operations despite increases in working capital. Investing cash flow of 6,531 million yen outflow was primarily driven by capital expenditures of 2,941 million yen and other investment activities. The CapEx to depreciation ratio of 0.40 indicates capital spending is running below depreciation of 7,349 million yen, suggesting potential underinvestment in asset renewal that warrants monitoring for long-term competitive positioning. Free cash flow of 8,646 million yen (operating CF minus investing CF) provides ample resources for shareholder returns and debt service. Financing cash flow reflected dividend payments and other capital allocation activities. Cash and deposits increased to 36,726 million yen, providing a strong liquidity cushion equivalent to 1.82 times coverage of short-term liabilities. Working capital showed mixed signals with accounts receivable of 18,315 million yen and inventory of 13,581 million yen representing significant operating capital tied up in the business. The cash conversion cycle metrics suggest opportunities for improvement in working capital efficiency, particularly in receivables collection and inventory turnover. Overall cash generation capacity remains strong, supporting both ongoing operations and capital allocation flexibility.
Ordinary income of 15,074 million yen versus operating income of 14,563 million yen shows a positive non-operating contribution of approximately 511 million yen. This comprises primarily interest income of 631 million yen, equity method investment gains, and other financial income, partially offset by foreign exchange losses of 271 million yen recorded in the period. Non-operating income represents 0.9% of revenue, a modest proportion indicating earnings are predominantly driven by core operations. The composition of non-operating income includes sustainable recurring elements such as interest and dividend income from cash deposits and investment securities holdings. Extraordinary income of 185 million yen from investment securities sales represents a non-recurring gain, comprising 1.7% of net income and not materially distorting core earnings. Operating cash flow of 15,177 million yen exceeding net income of 10,689 million yen by 42% indicates healthy earnings quality with strong cash realization. The effective tax rate of 29.6% is within normal corporate tax ranges without indication of unusual tax benefits artificially inflating earnings. Depreciation and amortization of 7,349 million yen represents a significant non-cash expense, with capital expenditure of 2,941 million yen running at only 40% of depreciation, suggesting conservative capital allocation that maintains reported profitability but may warrant attention for long-term asset base renewal.
Full-year guidance projects revenue of 75,500 million yen, operating income of 17,500 million yen, ordinary income of 17,600 million yen, and net income of 12,200 million yen. Q3 cumulative progress rates stand at 76.7% for revenue, 83.2% for operating income, 85.6% for ordinary income, and 87.6% for net income against full-year targets. With Q3 representing 75% of the fiscal year, the company is tracking ahead of schedule on profitability metrics while revenue is progressing in line with expectations. Operating income and net income are running approximately 8-13 percentage points ahead of the proportional quarterly pace, suggesting either strong Q3 performance or conservative full-year guidance. The implied Q4 would require revenue of 17,571 million yen, operating income of 2,937 million yen, ordinary income of 2,526 million yen, and net income of 1,511 million yen to meet targets. The Q4 implied operating margin of 16.7% would represent a sequential deceleration from Q3's 25.1%, possibly reflecting seasonal patterns, planned expenses, or conservative bufferring. Given the strong Q3 performance with operating margin expansion and robust cash flow, the company appears well-positioned to meet or exceed full-year guidance, particularly on profitability metrics. Full-year dividend guidance of 41 yen per share represents a payout ratio of approximately 24% based on forecast EPS of 346.04 yen, consistent with sustainable capital allocation policy.
The company paid an interim dividend of 35.0 yen per share and forecasts a year-end dividend of 38.0 yen per share, representing an annual total of 73.0 yen per share based on the cumulative payments. However, full-year guidance indicates 41.0 yen per share total annual dividend, suggesting the 73.0 yen figure may represent a different calculation basis or there is a reconciliation needed between interim actual and full-year forecast. Using the guidance figure of 41.0 yen per share against forecast net income of 12,200 million yen and forecast EPS of 346.04 yen yields a payout ratio of 11.8%. Using Q3 actual net income of 10,689 million yen (35,267 million shares outstanding) for annualized calculation would imply a payout ratio of approximately 24.1% at the 41 yen dividend level. Free cash flow of 8,646 million yen provides 3.34 times coverage of dividend payments, indicating strong sustainability. The company has not disclosed share buyback activity during the period. Dividend policy appears conservative with ample cash flow coverage and low payout ratio, providing room for potential future increases as earnings grow. The combination of strong profitability, robust cash generation, and low leverage supports sustainable and potentially growing shareholder returns over time.
Working capital efficiency deterioration poses operational risk, with Days Sales Outstanding, Days Inventory Outstanding, and Cash Conversion Cycle all extending year-over-year. Receivables of 18,315 million yen and inventory of 13,581 million yen represent significant capital tied up in operations. If collection periods continue extending or inventory accumulates further, this could pressure cash flow and operating efficiency despite currently strong cash generation. Segment concentration risk exists with Electronic Materials and Functional Chemicals now comprising 54.4% of revenue and 76.1% of segment profit. This segment serves semiconductor and electronics markets which are inherently cyclical. A downturn in electronics demand or semiconductor industry correction would disproportionately impact company performance. The Life Science segment's 4.0% revenue decline and stagnant profitability indicate challenges in this business line that require strategic attention. Capital expenditure discipline presents a medium-term risk, with CapEx running at only 40% of depreciation (2,941 million yen vs 7,349 million yen). While this enhances near-term profitability and cash flow, sustained underinvestment relative to asset base depreciation could lead to equipment obsolescence, production inefficiencies, or inability to pursue growth opportunities, potentially eroding competitive position over a 3-5 year horizon.
[Industry Position] (Reference - Proprietary Analysis)
The company demonstrates exceptional profitability relative to manufacturing industry peers. Operating margin of 25.1% substantially exceeds the industry median of 8.3%, placing the company in the top performance tier. Net profit margin of 18.5% is nearly triple the industry median of 6.3%, reflecting strong pricing power, operational efficiency, and favorable business mix. ROE of 9.4% outperforms the industry median of 5.0% by 4.4 percentage points, though remains below typical institutional investor thresholds of 10-15%. ROA of 7.2% more than doubles the industry median of 3.3%, indicating superior profit generation from asset base. Financial health metrics are notably stronger than industry norms. Equity ratio of 75.7% versus industry median of 63.8% reflects conservative capitalization with substantial financial cushion. Current ratio of 373.7% far exceeds the industry median of 2.84 times, indicating very strong liquidity position. Net debt to EBITDA is negative due to net cash position, comparing favorably to industry median of -1.11 times. Efficiency metrics reveal mixed positioning. Asset turnover of 0.388 falls below the industry median of 0.58, suggesting room for improvement in asset utilization intensity. Revenue growth of 10.5% significantly outpaces the industry median of 2.7%, placing the company among growth leaders. However, working capital metrics show challenges with inventory turnover extending beyond industry norms. CapEx to depreciation ratio of 0.40 is substantially below the industry median of 1.44, indicating relatively low reinvestment intensity that may pose long-term competitiveness questions. Overall, the company exhibits best-in-class profitability and financial stability while facing efficiency improvement opportunities in asset turnover and working capital management.
Industry: Manufacturing (N=98 companies), Comparison: FY2025 Q3 period data, Source: Proprietary analysis
Exceptional profitability profile with operating margin of 25.1% and net margin of 18.5% substantially exceeding manufacturing industry medians demonstrates strong competitive positioning and pricing power. The company ranks in the top tier of industry profitability metrics, generating ROE of 9.4% and ROA of 7.2% that both exceed peer medians despite conservative financial leverage. Revenue growth of 10.5% YoY significantly outpaces industry median of 2.7%, driven by 26.6% expansion in the Electronic Materials segment which has become the core business at 54.4% of revenue. Operating leverage is evident with profit growing faster than revenue (+15.6% vs +10.5%), indicating scalability of the business model. Strong cash generation characteristics are observable with operating cash flow representing 1.42 times net income and free cash flow of 8,646 million yen providing ample coverage for dividends and growth investment. The company maintains fortress balance sheet metrics including equity ratio of 75.7%, current ratio of 373.7%, and net cash position, providing substantial financial flexibility for strategic initiatives or weathering industry downturns.
Working capital management requires attention as evidenced by cash conversion ratio of 0.69 trailing industry median of 1.24 and inventory turnover metrics suggesting accumulation. Asset turnover of 0.388 below industry median of 0.58 indicates opportunities to improve asset productivity and ROIC. Capital expenditure intensity at 40% of depreciation raises questions about long-term asset renewal and growth capacity, as sustained underinvestment could constrain future competitiveness despite near-term cash flow benefits. Business mix shift toward Electronic Materials concentration (76.1% of segment profit) creates cyclical exposure to semiconductor and electronics markets, while Life Science segment decline of 4.0% suggests portfolio rebalancing needs. The gap between strong Q3 progress (87.6% of net income target) and full-year guidance implies either conservative planning or expected Q4 margin compression that warrants monitoring in subsequent quarterly results.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.